EGFR expression
|
SCCHN
|
EGFR expression
|
SCCHN
|
MRG003 Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks (NewC3)
|
MRG003 Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks - (New C3)
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
TPF Sensitive: A1 - Approval
|
TPF Sensitive: A1 - Approval
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
cetuximab Sensitive: A1 - Approval
|
cetuximab Sensitive: A1 - Approval
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
methotrexate Sensitive: A2 - Guideline
|
methotrexate Sensitive: A2 - Guideline
|
PD-L1 negative
|
SCCHN
|
PD-L1 negative
|
SCCHN
|
methotrexate Sensitive: A2 - Guideline
|
methotrexate Sensitive: A2 - Guideline
|
PD-L1 negative
|
SCCHN
|
PD-L1 negative
|
SCCHN
|
TPeX Sensitive: A2 - Guideline
|
TPeX Sensitive: A2 - Guideline
|
PD-L1 negative
|
SCCHN
|
PD-L1 negative
|
SCCHN
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 negative
|
SCCHN
|
PD-L1 negative
|
SCCHN
|
cetuximab Sensitive: A2 - Guideline
|
cetuximab Sensitive: A2 - Guideline
|
PD-L1 negative
|
SCCHN
|
PD-L1 negative
|
SCCHN
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
ADX-2191 Sensitive: A2 - Guideline
|
ADX-2191 Sensitive: A2 - Guideline
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
cetuximab Sensitive: A2 - Guideline
|
cetuximab Sensitive: A2 - Guideline
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
TPeX Sensitive: A2 - Guideline
|
TPeX Sensitive: A2 - Guideline
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
pembrolizumab + nivolumab Sensitive: A2 - Guideline
|
pembrolizumab + nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
carboplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
carboplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
AT-406 Sensitive: B - Late Trials
|
AT-406 Sensitive: B - Late Trials
|
CDKN2A negative
|
SCCHN
|
CDKN2A negative
|
SCCHN
|
panitumumab Sensitive: B - Late Trials
|
panitumumab Sensitive: B - Late Trials
|
HRAS mutation
|
SCCHN
|
HRAS mutation
|
SCCHN
|
tipifarnib Sensitive: B - Late Trials
|
tipifarnib Sensitive: B - Late Trials
|
TMB-H
|
SCCHN
|
TMB-H
|
SCCHN
|
durvalumab Sensitive: B - Late Trials
|
durvalumab Sensitive: B - Late Trials
|
TMB-H
|
SCCHN
|
TMB-H
|
SCCHN
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
TMB-H
|
SCCHN
|
TMB-H
|
SCCHN
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
KMT2D mutation
|
SCCHN
|
KMT2D mutation
|
SCCHN
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
EGFR amplification
|
SCCHN
|
EGFR amplification
|
SCCHN
|
afatinib Sensitive: B - Late Trials
|
afatinib Sensitive: B - Late Trials
|
ERBB3-L
|
SCCHN
|
ERBB3-L
|
SCCHN
|
afatinib Sensitive: B - Late Trials
|
afatinib Sensitive: B - Late Trials
|
CDKN2A negative
|
SCCHN
|
CDKN2A negative
|
SCCHN
|
afatinib Sensitive: B - Late Trials
|
afatinib Sensitive: B - Late Trials
|
PTEN-H
|
SCCHN
|
PTEN-H
|
SCCHN
|
afatinib Sensitive: B - Late Trials
|
afatinib Sensitive: B - Late Trials
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
durvalumab Sensitive: B - Late Trials
|
durvalumab Sensitive: B - Late Trials
|
ATM mutation
|
SCCHN
|
ATM mutation
|
SCCHN
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
eftilagimod alpha Sensitive: B - Late Trials
|
eftilagimod alpha Sensitive: B - Late Trials
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
durvalumab Sensitive: C1 - Off-label
|
durvalumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
EGFR expression
|
SCCHN
|
EGFR expression
|
SCCHN
|
cetuximab Sensitive: C1 - Off-label
|
cetuximab Sensitive: C1 - Off-label
|
EGFR overexpression
|
SCCHN
|
EGFR overexpression
|
SCCHN
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
|
SCCHN
|
TP53 mutation
|
SCCHN
|
AZD1775 Sensitive: C2 – Inclusion Criteria
|
AZD1775 Sensitive: C2 – Inclusion Criteria
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
durvalumab + CP-675206 Sensitive: C2 – Inclusion Criteria
|
durvalumab + CP-675206 Sensitive: C2 – Inclusion Criteria
|
EGFR amplification
|
SCCHN
|
EGFR amplification
|
SCCHN
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
PRSS3 underexpression
|
SCCHN
|
PRSS3 underexpression
|
SCCHN
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
TET1 mutation
|
SCCHN
|
TET1 mutation
|
SCCHN
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
pembrolizumab + eftilagimod alpha Sensitive: C3 – Early Trials
|
pembrolizumab + eftilagimod alpha Sensitive: C3 – Early Trials
|
EGFRvIII mutation
|
SCCHN
|
EGFRvIII mutation
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
AREG overexpression
|
SCCHN
|
AREG overexpression
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
EGFR mutation
|
SCCHN
|
EGFR mutation
|
SCCHN
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
NRG1 mutation
|
SCCHN
|
NRG1 mutation
|
SCCHN
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
HER-2 mutation
|
SCCHN
|
HER-2 mutation
|
SCCHN
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
MET positive
|
SCCHN
|
MET positive
|
SCCHN
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
TP53 mutation
|
SCCHN
|
TP53 mutation
|
SCCHN
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
TMB-H
|
SCCHN
|
TMB-H
|
SCCHN
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
SCCHN
|
PD-L1 underexpression
|
SCCHN
|
cetuximab sarotalocan Sensitive: C3 – Early Trials
|
cetuximab sarotalocan Sensitive: C3 – Early Trials
|
EGFR R521K
|
SCCHN
|
EGFR R521K
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
DDR2 overexpression
|
SCCHN
|
DDR2 overexpression
|
SCCHN
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|
ERBB3 mutation
|
SCCHN
|
ERBB3 mutation
|
SCCHN
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
SMARCA4 mutation + MSI-L/dMMR
|
SCCHN
|
SMARCA4 mutation + MSI-L/dMMR
|
SCCHN
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
ROS1 mutation + MSI-L/dMMR
|
SCCHN
|
ROS1 mutation + MSI-L/dMMR
|
SCCHN
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
PD-L2 overexpression
|
SCCHN
|
PD-L2 overexpression
|
SCCHN
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
Choline elevation
|
SCCHN
|
Choline elevation
|
SCCHN
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
IFNG RNA sig
|
SCCHN
|
IFNG RNA sig
|
SCCHN
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L1 expression
|
SCCHN
|
PD-L1 expression
|
SCCHN
|
pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials
|
pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials
|
IL1A elevation
|
SCCHN
|
IL1A elevation
|
SCCHN
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
FGFR overexpression
|
SCCHN
|
FGFR overexpression
|
SCCHN
|
BAY 1163877 Sensitive: C3 – Early Trials
|
BAY 1163877 Sensitive: C3 – Early Trials
|
CXCL8 expression
|
SCCHN
|
CXCL8 expression
|
SCCHN
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
MET N375S
|
SCCHN
|
MET N375S
|
SCCHN
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PTEN expression
|
SCCHN
|
PTEN expression
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
KRAS mutation
|
SCCHN
|
KRAS mutation
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
HRAS mutation
|
SCCHN
|
HRAS mutation
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
olaparib Resistant: C3 – Early Trials
|
olaparib Resistant: C3 – Early Trials
|
PD-L1 overexpression
|
SCCHN
|
PD-L1 overexpression
|
SCCHN
|
durvalumab + CP-675206 Sensitive: C3 – Early Trials
|
durvalumab + CP-675206 Sensitive: C3 – Early Trials
|
ATM mutation
|
SCCHN
|
ATM mutation
|
SCCHN
|
durvalumab Sensitive: C3 – Early Trials
|
durvalumab Sensitive: C3 – Early Trials
|
AREG expression
|
SCCHN
|
AREG expression
|
SCCHN
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
SMAD4 expression
|
SCCHN
|
SMAD4 expression
|
SCCHN
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
TLR4 overexpression
|
SCCHN
|
TLR4 overexpression
|
SCCHN
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PIK3CA E542K
|
SCCHN
|
PIK3CA E542K
|
SCCHN
|
GDC-0980 Sensitive: C3 – Early Trials
|
GDC-0980 Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
SCCHN
|
PIK3CA mutation
|
SCCHN
|
cetuximab + alpelisib Sensitive: C3 – Early Trials
|
cetuximab + alpelisib Sensitive: C3 – Early Trials
|
FANCI mutation + FLT1 mutation
|
SCCHN
|
FANCI mutation + FLT1 mutation
|
SCCHN
|
AN2025 Sensitive: C3 – Early Trials
|
AN2025 Sensitive: C3 – Early Trials
|
FANCA mutation + FGFR3 mutation
|
SCCHN
|
FANCA mutation + FGFR3 mutation
|
SCCHN
|
AN2025 Sensitive: C3 – Early Trials
|
AN2025 Sensitive: C3 – Early Trials
|
FANCD2 mutation + EP300 mutation
|
SCCHN
|
FANCD2 mutation + EP300 mutation
|
SCCHN
|
AN2025 Sensitive: C3 – Early Trials
|
AN2025 Sensitive: C3 – Early Trials
|
PIK3CA mutation + EP300 mutation
|
SCCHN
|
PIK3CA mutation + EP300 mutation
|
SCCHN
|
AN2025 Sensitive: C3 – Early Trials
|
AN2025 Sensitive: C3 – Early Trials
|
IFNG overexpression
|
SCCHN
|
IFNG overexpression
|
SCCHN
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
IDO1 overexpression
|
SCCHN
|
IDO1 overexpression
|
SCCHN
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
IFI35 overexpression
|
SCCHN
|
IFI35 overexpression
|
SCCHN
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
OASL overexpression
|
SCCHN
|
OASL overexpression
|
SCCHN
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
CXCL9 overexpression
|
SCCHN
|
CXCL9 overexpression
|
SCCHN
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|